genetics_institute inc. , cambridge , mass. , said_0 it was awarded u.s. patents for interleukin-3 and bone morphogenetic protein . the patent for interleukin-3 covers materials and methods used to make the human blood cell growth factor via recombinant dna technology . sandoz ltd. has licensed certain manufacturing and marketing rights for interleukin-3 from genetics_institute and is conducting preclinical studies with it . interleukin-3 may help in treating blood cell deficiencies associated_with cancer treatment , bone marrow transplants and other blood-cell disorders , genetics_institute said_0 . the second patent describes bone morphogenetic protein-1 , a substance that can induce formation of new cartilage . the patent covers bmp-1 type proteins and pharmaceutical compositions and methods for treating bone or cartilage defects , genetics_institute said_0 . the company added that it has filed patent applications `` on a large_number of different bmp proteins '' and the patent on bmp-1 is the first 0 it has received . bmp products may_be useful in fracture healing and in treating bone loss associated_with periodontal disease and certain cancers , the company said_0 .